SNA 001
Alternative Names: SNA001; SNA001 rhTSHLatest Information Update: 22 Aug 2023
At a glance
- Originator SmartNuclide Biopharma
- Class Antineoplastics; Diagnostic agents; Recombinant proteins
- Mechanism of Action Thyrotropin-releasing hormone stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preregistration Thyroid cancer
Most Recent Events
- 22 Aug 2023 Preregistration for Thyroid cancer in China (Parenteral)
- 25 Jul 2022 Phase-II clinical trials in Thyroid cancer (Diagnosis) in China (Parenteral) (SmartNuclide Biopharma pipeline, July 2022)
- 25 Jul 2022 SmartNuclide Biopharma plans to file a BLA for Thyroid cancer (SmartNuclide Biopharma pipeline, July 2022)